Get the Stockscreener App
34.17
1.95%
-0.68
Bridgebio Pharma Inc stock is traded at $34.17, with a volume of 1.79M.
It is down -1.95% in the last 24 hours and up +3.92% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$34.85
Open:
$35.43
24h Volume:
1.79M
Relative Volume:
0.59
Market Cap:
$7.32B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-14.18
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
-11.41%
1M Performance:
+3.92%
6M Performance:
+26.14%
1Y Performance:
+18.93%
1-Day Range:
$34.15
$35.60
1-Week Range:
$33.92
$38.73
52-Week Range:
$21.62
$39.54
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
34.17 | 7.32B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 - The Manila Times
Achondroplasia Market: Epidemiology, Therapies, Companies, - openPR.com
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating - marketscreener.com
Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga
BridgeBio (BBIO) Sees Surge in Bullish Option Activity | BBIO Stock News - GuruFocus
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update - ADVFN
BridgeBio Pharma Stock (BBIO) Jumps on Strong Drug Launch - The Globe and Mail
Cantor Fitzgerald Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q1 2025 Earnings Call Transcript - Insider Monkey
High Growth Tech Stocks In The US Market May 2025 - simplywall.st
BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN
Excellent Earnings Propelled Prices of These 10 Firms - Insider Monkey
BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales - insights.citeline.com
Decoding BridgeBio Pharma Inc (BBIO): A Strategic SWOT Insight - GuruFocus
BridgeBio sales of new heart drug outstrip expectations - BioPharma Dive
BridgeBio (BBIO) Price Target Increased by Scotiabank Analyst | - GuruFocus
Attruby's Momentum and an Advancing Pipeline Support BridgeBio's Long-Term Growth Outlook - Morningstar
UBS Raises Price Target for BridgeBio (BBIO) Amid Strong Q1 Perf - GuruFocus
UBS Adjusts Price Target on BridgeBio Pharma to $72 From $65, Maintains Buy Rating - marketscreener.com
BridgeBio (BBIO) Price Target Uplifted by BofA Analyst Amid Stro - GuruFocus
Scotiabank raises BridgeBio stock target to $55 on strong sales By Investing.com - Investing.com India
Scotiabank raises BridgeBio stock target to $55 on strong sales - Investing.com
BridgeBio price target raised to $63 from $46 at Piper Sandler - TipRanks
BridgeBio (BBIO) Target Price Increased by Piper Sandler Followi - GuruFocus
BridgeBio (BBIO) Target Price Increased by Piper Sandler Following Strong Quarter | BBIO Stock News - GuruFocus
BridgeBio’s Attruby outperforms sales expectations, shares rise - Endpoints News
BridgeBio Pharma’s Attruby Outperforms Expectations, Analyst Raises Price Target to $50 - TipRanks
(BBIO) Trading Advice - news.stocktradersdaily.com
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: St - GuruFocus
BridgeBio Pharma: Q1 Earnings Snapshot - CT Insider
BridgeBio Pharma Reports Q1 2025 Earnings and Pipeline Progress - TipRanks
Earnings call transcript: BridgeBio Q1 2025 shows strong revenue growth By Investing.com - Investing.com Nigeria
Earnings call transcript: BridgeBio Q1 2025 shows strong revenue growth - Investing.com
BridgeBio Pharma, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma (BBIO) Reports Strong Q1 Earnings, Shares Rise - GuruFocus
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
BridgeBio Pharma, Inc. SEC 10-Q Report - TradingView
BridgeBio Pharma Q1 Loss Widens, Revenue Drops - marketscreener.com
BridgeBio (BBIO) Exceeds Revenue Expectations with Strong Prescr - GuruFocus
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates - The Manila Times
BridgeBio Reports Blockbuster Q1: New Drug Attruby Surges with 2,072 Patient Scripts, Pipeline Advances - Stock Titan
BridgeBio (BBIO) Anticipates Significant Post-Earnings Volatilit - GuruFocus
BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - MSN
UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM - Yahoo Finance
BridgeBio Pharma (BBIO) Set to Release Q1 Earnings Report - GuruFocus
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Report Preview: Wha - GuruFocus
A Look Ahead: BridgeBio Pharma's Earnings Forecast - Benzinga
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bridgebio Pharma Inc Stock (BBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lo Andrew | Director |
May 02 '25 |
Sale |
38.50 |
100,000 |
3,849,900 |
105,583 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):